Save on this medicine
Other brands with the same active ingredient
These brands contain the same active ingredient (Erdafitinib). Strength and form may differ — confirm substitution with your doctor or pharmacist before switching.
Indications & Uses
Erdanib-4 is indicated for:
Dosage Reference
Reference Information Only
Dosages shown are general references from official sources. Always consult your doctor or pharmacist for personalized dosing.
Adults:
The recommended starting dose of Erdafitinib is 8 mg (two 4 mg tablets) orally once daily, with a dose increase to 9 mg (three 3 mg tablets) once daily based on serum phosphate (PO4) levels and tolerability at 14 to 21 days. Treatment should be continued until disease progression or unacceptable toxicity occurs. If a dose of Erdafitinib is missed, it can be taken as soon as possible on the same day. The regular daily dose schedule for Erdafitinib should be resumed the next day. Extra tablets should not be taken to make up for the missed dose.
Side Effects
The most common adverse reactions including laboratory abnormalities (≥20%) are elevated phosphate, stomatitis, fatigue, elevated creatinine, diarrhea, dry mouth, nail disorder, elevated alanine aminotransferase, elevated alkaline phosphatase, decrease in sodium, decrease in appetite, decrease in albumin, dysgeusia, decrease in hemoglobin, dry skin, elevated aspartate aminotransferase, decrease in magnesium, dry eye, alopecia, palmar-plantar erythrodysesthesia syndrome, constipation, decrease in phosphate, abdominal pain, elevated calcium, nausea, and musculoskeletal pain.
Cautions & Contraindications
Warnings & Precautions
Ocular disorders: Erdafixen can cause central serous retinopathy/retinal pigment epithelial detachment (CSR/RPED). Monthly ophthalmological examinations should be performed during the first four months of treatment, every 3 months afterwards, and at any time for visual symptoms. When CSR/RPED occurs, Erdafixen should be withheld and permanently discontinued if it does not resolve within 4 weeks or if Grade 4 in severity.Hyperphosphatemia: Hyperphosphatemia should be monitored and managed with dose modifications when required.Embryo-fetal toxicity: Since it can cause fetal harms so patients of the potential risk to the fetus should be advised to use effective contraception.